Cargando…

Data Recorded in Real Life Support the Safety of Nattokinase in Patients with Vascular Diseases

Nattokinase (NK) is a serine protease enzyme with fibrinolytic activity. Even if it could be used for the treatment of several diseases, no data have been published supporting its use patients who underwent vascular surgery. In this study, we evaluated both the efficacy and the safety of nattokinase...

Descripción completa

Detalles Bibliográficos
Autores principales: Gallelli, Giuseppe, Di Mizio, Giulio, Palleria, Caterina, Siniscalchi, Antonio, Rubino, Paolo, Muraca, Lucia, Cione, Erika, Salerno, Monica, De Sarro, Giovambattista, Gallelli, Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8231931/
https://www.ncbi.nlm.nih.gov/pubmed/34199189
http://dx.doi.org/10.3390/nu13062031
_version_ 1783713528663769088
author Gallelli, Giuseppe
Di Mizio, Giulio
Palleria, Caterina
Siniscalchi, Antonio
Rubino, Paolo
Muraca, Lucia
Cione, Erika
Salerno, Monica
De Sarro, Giovambattista
Gallelli, Luca
author_facet Gallelli, Giuseppe
Di Mizio, Giulio
Palleria, Caterina
Siniscalchi, Antonio
Rubino, Paolo
Muraca, Lucia
Cione, Erika
Salerno, Monica
De Sarro, Giovambattista
Gallelli, Luca
author_sort Gallelli, Giuseppe
collection PubMed
description Nattokinase (NK) is a serine protease enzyme with fibrinolytic activity. Even if it could be used for the treatment of several diseases, no data have been published supporting its use patients who underwent vascular surgery. In this study, we evaluated both the efficacy and the safety of nattokinase (100 mg/day per os) in patients admitted to vascular surgery. Patients were of both sexes, >18 years of age, with vascular diseases (i.e., deep vein thrombosis, superficial vein thrombosis, venous insufficiency), and naïve to specific pharmacological treatments (anticoagulants or anti-platelets). Patients were divided into three groups. Group 1: patients with deep vein thrombosis, treated with fondaparinux plus nattokinase. Group 2: patients with phlebitis, treated with enoxaparin plus nattokinase. Group 3: patients with venous insufficiency after classical surgery, treated with nattokinase one day later. During the study, we enrolled 153 patients (age 22–92 years), 92 females (60.1%) and 61 males (39.9%;), and documented that nattokinase was able to improve the clinical symptoms (p < 0.01) without the development of adverse drug reactions or drug interactions. Among the enrolled patients, during follow-up, we did not record new cases of vascular diseases. Attention to patients’ clinical evolution, monitoring of the INR, and timely and frequent adjustment of dosages represent the cornerstones of the safety of care for patients administered fibrinolytic drugs as a single treatment or in pharmacological combination. Therefore, we can conclude that the use of nattokinase represents an efficient and safe treatment able to both prevent and treat patients with vascular diseases.
format Online
Article
Text
id pubmed-8231931
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-82319312021-06-26 Data Recorded in Real Life Support the Safety of Nattokinase in Patients with Vascular Diseases Gallelli, Giuseppe Di Mizio, Giulio Palleria, Caterina Siniscalchi, Antonio Rubino, Paolo Muraca, Lucia Cione, Erika Salerno, Monica De Sarro, Giovambattista Gallelli, Luca Nutrients Article Nattokinase (NK) is a serine protease enzyme with fibrinolytic activity. Even if it could be used for the treatment of several diseases, no data have been published supporting its use patients who underwent vascular surgery. In this study, we evaluated both the efficacy and the safety of nattokinase (100 mg/day per os) in patients admitted to vascular surgery. Patients were of both sexes, >18 years of age, with vascular diseases (i.e., deep vein thrombosis, superficial vein thrombosis, venous insufficiency), and naïve to specific pharmacological treatments (anticoagulants or anti-platelets). Patients were divided into three groups. Group 1: patients with deep vein thrombosis, treated with fondaparinux plus nattokinase. Group 2: patients with phlebitis, treated with enoxaparin plus nattokinase. Group 3: patients with venous insufficiency after classical surgery, treated with nattokinase one day later. During the study, we enrolled 153 patients (age 22–92 years), 92 females (60.1%) and 61 males (39.9%;), and documented that nattokinase was able to improve the clinical symptoms (p < 0.01) without the development of adverse drug reactions or drug interactions. Among the enrolled patients, during follow-up, we did not record new cases of vascular diseases. Attention to patients’ clinical evolution, monitoring of the INR, and timely and frequent adjustment of dosages represent the cornerstones of the safety of care for patients administered fibrinolytic drugs as a single treatment or in pharmacological combination. Therefore, we can conclude that the use of nattokinase represents an efficient and safe treatment able to both prevent and treat patients with vascular diseases. MDPI 2021-06-13 /pmc/articles/PMC8231931/ /pubmed/34199189 http://dx.doi.org/10.3390/nu13062031 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Gallelli, Giuseppe
Di Mizio, Giulio
Palleria, Caterina
Siniscalchi, Antonio
Rubino, Paolo
Muraca, Lucia
Cione, Erika
Salerno, Monica
De Sarro, Giovambattista
Gallelli, Luca
Data Recorded in Real Life Support the Safety of Nattokinase in Patients with Vascular Diseases
title Data Recorded in Real Life Support the Safety of Nattokinase in Patients with Vascular Diseases
title_full Data Recorded in Real Life Support the Safety of Nattokinase in Patients with Vascular Diseases
title_fullStr Data Recorded in Real Life Support the Safety of Nattokinase in Patients with Vascular Diseases
title_full_unstemmed Data Recorded in Real Life Support the Safety of Nattokinase in Patients with Vascular Diseases
title_short Data Recorded in Real Life Support the Safety of Nattokinase in Patients with Vascular Diseases
title_sort data recorded in real life support the safety of nattokinase in patients with vascular diseases
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8231931/
https://www.ncbi.nlm.nih.gov/pubmed/34199189
http://dx.doi.org/10.3390/nu13062031
work_keys_str_mv AT gallelligiuseppe datarecordedinreallifesupportthesafetyofnattokinaseinpatientswithvasculardiseases
AT dimiziogiulio datarecordedinreallifesupportthesafetyofnattokinaseinpatientswithvasculardiseases
AT palleriacaterina datarecordedinreallifesupportthesafetyofnattokinaseinpatientswithvasculardiseases
AT siniscalchiantonio datarecordedinreallifesupportthesafetyofnattokinaseinpatientswithvasculardiseases
AT rubinopaolo datarecordedinreallifesupportthesafetyofnattokinaseinpatientswithvasculardiseases
AT muracalucia datarecordedinreallifesupportthesafetyofnattokinaseinpatientswithvasculardiseases
AT cioneerika datarecordedinreallifesupportthesafetyofnattokinaseinpatientswithvasculardiseases
AT salernomonica datarecordedinreallifesupportthesafetyofnattokinaseinpatientswithvasculardiseases
AT desarrogiovambattista datarecordedinreallifesupportthesafetyofnattokinaseinpatientswithvasculardiseases
AT gallelliluca datarecordedinreallifesupportthesafetyofnattokinaseinpatientswithvasculardiseases